NCT05673603View on ClinicalTrials.gov

A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 20, 2021

Primary Completion Date

February 14, 2023

Study Completion Date

February 14, 2023

Conditions
Renal Impairment
Interventions
DRUG

Brensocatib

Oral tablet

Trial Locations (3)

32809

USA002, Orlando

33603

USA003, Tampa

78215

USA001, San Antonio

All Listed Sponsors
lead

Insmed Incorporated

INDUSTRY

NCT05673603 - A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment | Biotech Hunter | Biotech Hunter